Needham initiated coverage on Inari Medical Inc (NASDAQ:NARI), noting it as a leader in the very large and underpenetrated market for venous thrombectomy.
Inari Medical projects an annual patient population of 280,000 with pulmonary embolism (PE) in the U.S., equating to a total available market (TAM) of $2.8 billion for its FlowTriever product.
Additionally, the company estimates a yearly count of 430,000 patients with deep vein thrombosis (DVT), resulting in a $3.0 billion TAM for its ClotTriever product. The penetration rates for the PE and DVT markets are approximately 20% and 15%, respectively.
Needham initiates with a Buy rating and a price target of $72.
In late 2023, Inari Medical acquired LimFlow SA for $250 million in cash at closing and is ...